Comparison of Bleeding Risk Between Rivaroxaban and Apixaban
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood
thinners for the treatment of blood clots. Half of the patients will receive apixaban and
half will receive rivaroxaban. The main objective is to determine the feasibility of patient
recruitment and resources required to follow enrolled patients and inform for a larger,
multi-centered trial and to assess which one is safer.
Phase:
Phase 4
Details
Lead Sponsor:
Ottawa Hospital Research Institute
Collaborators:
Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network